Cronos Group Posts Record 2025 Revenue and Eyes European Cannabis Expansion
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cronos Group ( (TSE:CRON) ) has provided an update.
Cronos Group reported record fourth-quarter and full-year 2025 net revenue, with Q4 sales rising 47% year over year to $44.5 million and full-year revenue up 25% to $146.6 million, driven by strong demand for its leading brands, expanded output from Cronos GrowCo and growing international contributions, particularly in Israel. The company significantly improved profitability metrics, turning Adjusted EBITDA positive for the year, while maintaining an industry-leading cash position of $832 million plus short-term investments, which, along with the pending acquisition of European operator CanAdelaar and its Netherlands adult-use strategy, is expected to strengthen its competitive footing and support sustained growth and long-term value creation.
The most recent analyst rating on (TSE:CRON) stock is a Buy with a C$4.50 price target. To see the full list of analyst forecasts on Cronos Group stock, see the TSE:CRON Stock Forecast page.
Spark’s Take on TSE:CRON Stock
According to Spark, TipRanks’ AI Analyst, TSE:CRON is a Neutral.
Cronos Group’s overall score reflects strong earnings performance and technical momentum, offset by valuation concerns and cash flow challenges. The company’s robust market position in Canada and Israel, coupled with a strong balance sheet, supports future growth, but operational profitability and cash flow issues need resolution.
To see Spark’s full report on TSE:CRON stock, click here.
More about Cronos Group
Cronos Group Inc., listed on Nasdaq and the TSX, operates in the global cannabis industry with a focus on branded cannabis products and international markets. Its portfolio includes the PEACE NATURALS brand, which holds the top market position in Israel’s medical cannabis segment, and it is expanding cultivation capacity through Cronos GrowCo to support growth across key regions.
Average Trading Volume: 242,052
Technical Sentiment Signal: Buy
Current Market Cap: C$1.43B
See more insights into CRON stock on TipRanks’ Stock Analysis page.
